Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | TERT | O14746 | 2/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.60 |
| ▸ | DTYMK | P23919 | 4/20 | 0.59 |
| ▸ | TK1 | P04183 | 3/20 | 0.54 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.52 |
| ▸ | TYMS | P04818 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534179 | 1.00 | F2 (0.63) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29671382 | 0.96 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29350192 | 0.96 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29415903 | 0.96 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29775052 | 0.96 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL34463741 | 0.96 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29369996 | 0.94 | F2 (0.62) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29372542 | 0.94 | F2 (0.62) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29357819 | 0.94 | F2 (0.62) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL30211177 | 0.94 | F2 (0.62) | F2POLBTERTP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3674404-B1 | TARGET SEQUENCE SPECIFIC ALTERATION TECHNOLOGY USING NUCLEOTIDE TARGET RECOGNITION | UNIV TOKUSHIMA (JP) | 2025-10-15 | — | — | EP | claimed |
| US-12247200-B2 | Compositions and methods for generating massively parallel nucleic acid sequencing libraries | BIOO SCIENTIFIC CORPORATION (US) | 2025-03-11 | — | — | US | claimed |
| US-12215315-B2 | Method for modifying target nucleic acid in genome of cell | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2025-02-04 | — | — | US | claimed |
| US-20240327828-A1 | TARGET SEQUENCE SPECIFIC ALTERATION TECHNOLOGY USING NUCLEOTIDE TARGET RECOGNITION | UNIV TOKUSHIMA (JP) | 2024-10-03 | — | — | US | claimed |
| US-12012596-B2 | Target sequence specific alteration technology using nucleotide target recognition | TOKUSHIMA UNIVERSITY (JP) | 2024-06-18 | — | — | US | claimed |
| CN-116381228-A | Reagent for capturing and detecting circulating exosomes and application thereof | 上海大学 | 2023-07-04 | — | — | CN | claimed |
| CN-114667149-A | Novel nucleobase editor and methods of use | 比姆医疗股份有限公司 | 2022-06-24 | — | — | CN | claimed |
| WO-2026099341-A1 | BIOCONTAINMENT OF UNWANTED ENGINEERED CELLS USING NON-NATURAL AMINO ACIDS | SNIPR BIOME APS (DK) | 2026-05-15 | — | — | WO | disclosed |
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | APTAH BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | APTAH BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4652277-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Aptah Bio, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4652278-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | Aptah Bio, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-3674404-B1 | TARGET SEQUENCE SPECIFIC ALTERATION TECHNOLOGY USING NUCLEOTIDE TARGET RECOGNITION | UNIV TOKUSHIMA (JP) | 2025-10-15 | — | — | EP | disclosed |
| CN-116096873-A | Methods and compositions for editing two strands of a target double-stranded nucleotide sequence simultaneously | 布罗德研究所股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230047776-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR GENE EXPRESSION REGULATIONS | APTAH BIO, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2023288111-A2 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR GENE EXPRESSION REGULATION | APTAH BIO, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-114667149-A | Novel nucleobase editor and methods of use | 比姆医疗股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-11365452-B2 | Composition for diagnosing or predicting risk of metabolic syndrome or metabolic syndrome-related diseases using human oral microbiome | KOBIOLABS, INC. (KR) | 2022-06-21 | — | — | US | disclosed |
| WO-2022075419-A1 | TECHNIQUE FOR MODIFYING TARGET NUCLEOTIDE SEQUENCE USING CRISPR-TYPE I-D SYSTEM | 国立大学法人徳島大学 | 2022-04-14 | — | — | WO | disclosed |
| EP-3978624-A1 | METHYLATED CONTROL DNA | Exact Sciences Corporation (US) | 2022-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085315-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | RPRD2, RTCB, UPF1 | F2 3290/4885POLB 224/4885TERT 723/4885 |
| US-20260022377-A1 | POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | PRNP, UPF1, FUS | F2 1620/4885POLB 387/4885TERT 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.